SOTORASIB

Information current as at: 1 June 2026

The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.

PBAC meeting date: November 2022

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Lumakras®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: AMGEN AUSTRALIA PTY LIMITED
Condition/indication: (therapeutic use): Non-small cell lung cancer
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: November 2022 PBAC meeting
Opportunity for consumer comment:: Open 27/07/2022 and close 21/09/2022 (see PBS Website)
PBAC meeting:: Not applicable
PBAC outcome published:: Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a608

Page last updated

31 March 2026

v.9.19